The Prognostic, Diagnostic, and Therapeutic Potential of TRAIL Signalling in Cardiovascular Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Apr 13

PMID 37047698

Authors

Elaina Kelland

Manisha S Patil

Sanjay Patel

Sian P Cartland

Mary M Kavurma

Affiliations

Soon will be listed here.

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) was originally discovered, almost 20 years ago, for its ability to kill cancer cells. More recent evidence has described pleiotropic functions, particularly in the cardiovascular system. There is potential for TRAIL concentrations in the circulation to act as prognostic and/or diagnostic factors for cardiovascular diseases (CVD). Pre-clinical studies also describe the therapeutic capacity for TRAIL signals, particularly in the context of atherosclerotic disease and diseases of the myocardium. Because diabetes mellitus significantly contributes to the progression and pathogenesis of CVDs, in this review we highlight recent evidence for the prognostic, diagnostic, and therapeutic potential of TRAIL signals in CVDs, and where relevant, the impact of diabetes mellitus. A greater understanding of how TRAIL signals regulate cardiovascular protection and pathology may offer new diagnostic and therapeutic avenues for patients suffering from CVDs.

Citing Articles

Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.

Kolossvary M, Schnittman S, Zanni M, Fitch K, Fichtenbaum C, Aberg J JAMA Cardiol. 2024; 10(3):254-264.

PMID: 39661372 PMC: 11771813. DOI: 10.1001/jamacardio.2024.4115.

Cytoplasmic TP53INP2 acts as an apoptosis partner in TRAIL treatment: the synergistic effect of TRAIL with venetoclax in TP53INP2-positive acute myeloid leukemia.

Ren J, Huang J, Yang Z, Sun M, Yang J, Lin C J Exp Clin Cancer Res. 2024; 43(1):176.

PMID: 38909249 PMC: 11193246. DOI: 10.1186/s13046-024-03100-0.

Guerrache A, Micheau O Cells. 2024; 13(6.

PMID: 38534365 PMC: 10968836. DOI: 10.3390/cells13060521.

Endothelial Cell Apoptosis but Not Necrosis Is Inhibited by Ischemic Preconditioning.

Zalewski J, Szajna M, Stepien K, Nowak K, Karcinska A, Del Carmen Yika A Int J Mol Sci. 2024; 25(2).

PMID: 38279236 PMC: 10816637. DOI: 10.3390/ijms25021238.

References

Chen Y, Zhou X, Qiao J, Bao A . Autophagy is a regulator of TRAIL-induced apoptosis in NSCLC A549 cells. J Cell Commun Signal. 2017; 11(3):219-226. PMC: 5559391. DOI: 10.1007/s12079-016-0364-4. View

Ferreira J, Sharma A, Mehta C, Bakris G, Rossignol P, White W . Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2020; 110(7):1006-1019. DOI: 10.1007/s00392-020-01729-3. View

Richter B, Koller L, Hohensinner P, Zorn G, Brekalo M, Berger R . A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol. 2012; 168(2):1251-7. DOI: 10.1016/j.ijcard.2012.11.052. View

Kahraman S, Yilmaz O, Altunbas H, Dirice E, Sanlioglu A . TRAIL induces proliferation in rodent pancreatic beta cells via AKT activation. J Mol Endocrinol. 2021; 66(4):325-338. DOI: 10.1530/JME-20-0037. View

Di Bartolo B, Chan J, Bennett M, Cartland S, Bao S, Tuch B . TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe ⁻/⁻ mice. Diabetologia. 2011; 54(12):3157-67. DOI: 10.1007/s00125-011-2308-0. View

Goncalves I, Singh P, Tengryd C, Cavalera M, Mattisson I, Nitulescu M . sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a Marker of Plaque Cell Apoptosis and Cardiovascular Events. Stroke. 2019; 50(8):1989-1996. DOI: 10.1161/STROKEAHA.119.024379. View

Spierings D, de Vries E, Vellenga E, van den Heuvel F, Koornstra J, Wesseling J . Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem. 2004; 52(6):821-31. DOI: 10.1369/jhc.3A6112.2004. View

Shen A, Hou X, Yang D, Liu T, Zheng D, Deng L . Role of osteoprotegerin and its gene polymorphisms in the occurrence of left ventricular hypertrophy in essential hypertensive patients. Medicine (Baltimore). 2014; 93(29):e154. PMC: 4602608. DOI: 10.1097/MD.0000000000000154. View

Di Bartolo B, Cartland S, Prado-Lourenco L, Griffith T, Gentile C, Ravindran J . Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms. J Am Heart Assoc. 2015; 4(11). PMC: 4845240. DOI: 10.1161/JAHA.115.002527. View

10.

Niessner A, Hohensinner P, Rychli K, Neuhold S, Zorn G, Richter B . Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009; 30(7):789-96. DOI: 10.1093/eurheartj/ehp004. View

11.

Snajdauf M, Havlova K, Vachtenheim Jr J, Ozaniak A, Lischke R, Bartunkova J . The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front Mol Biosci. 2021; 8:628332. PMC: 8006409. DOI: 10.3389/fmolb.2021.628332. View

12.

Rewiuk K, Grodzicki T . Osteoprotegerin and TRAIL in Acute Onset of Atrial Fibrillation. Biomed Res Int. 2015; 2015:259843. PMC: 4609353. DOI: 10.1155/2015/259843. View

13.

Xiang G, Zhang J, Ling Y, Zhao L . Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients. Clin Endocrinol (Oxf). 2013; 80(2):228-34. DOI: 10.1111/cen.12312. View

14.

Skau E, Henriksen E, Wagner P, Hedberg P, Siegbahn A, Leppert J . GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. Eur J Prev Cardiol. 2017; 24(15):1576-1583. DOI: 10.1177/2047487317725017. View

15.

Pan G, Ni J, Wei Y, Yu G, Gentz R, Dixit V . An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997; 277(5327):815-8. DOI: 10.1126/science.277.5327.815. View

16.

Kuzniewski M, Fedak D, Dumnicka P, Stepien E, Kusnierz-Cabala B, Cwynar M . Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Adv Med Sci. 2016; 61(2):269-275. DOI: 10.1016/j.advms.2016.03.003. View

17.

OSullivan E, Ashley D, Davenport C, Kelly J, Devlin N, Crowley R . Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res. 2010; 126(6):e423-7. DOI: 10.1016/j.thromres.2010.09.003. View

18.

Arik H, Yalcin A, Gumuslu S, Genc G, Turan A, Sanlioglu A . Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers. Med Sci Monit. 2013; 19:712-5. PMC: 3762395. DOI: 10.12659/MSM.889514. View

19.

Kavurma M, Schoppet M, Bobryshev Y, Khachigian L, Bennett M . TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor. J Biol Chem. 2008; 283(12):7754-62. DOI: 10.1074/jbc.M706927200. View

20.

Fossati S, Ghiso J, Rostagno A . TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ. Cell Death Dis. 2012; 3:e321. PMC: 3388229. DOI: 10.1038/cddis.2012.55. View